SCHEMBL689798

SCHEMBL689798

c1onnc1C1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.44
USP7 Q93009 2/20 0.41
SLC18A3 Q16572 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
PLG P00747 3/20 0.35
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MKNK1 Q9BUB5 2/20 0.33
MKNK2 Q9HBH9 2/20 0.33
PLAT P00750 1/20 0.33
HTR2C P28335 2/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperidine SCHEMBL2494101 0.87 HRH4 (0.38) HRH4USP7HRH3
SCHEMBL2202748 0.85
SCHEMBL5660853 0.81
SCHEMBL16992452 0.68 SLC18A3 (0.41) HRH4USP7SLC18A3SIGMAR1HRH3
SCHEMBL3635390 0.66
SCHEMBL16400229 0.65 USP7 (0.53) HRH4USP7SLC18A3SIGMAR1HRH3
SCHEMBL7447247 0.65 HRH4 (0.42) HRH4USP7SLC18A3SIGMAR1HRH3
SCHEMBL4407368 0.65 CYP2D6 (0.41) SLC18A3HRH3
SCHEMBL6237485 0.63
SCHEMBL20037971 0.63 HRH4 (0.40) HRH4USP7SLC18A3SIGMAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178361-A Preparation of piperidine bisoxadiazole and piperidine amino thiazole substituted antitumor curcumenol derivatives and application thereof in antitumor 华东理工大学 2023-05-30 CN disclosed
EP-1951718-B9 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA LP (US) 2012-08-15 EP disclosed
EP-1951718-B9 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA LP (US) 2012-08-15 EP disclosed
EP-1951718-B1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA LP (US) 2012-02-29 EP disclosed
EP-1951718-B1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA LP (US) 2012-02-29 EP disclosed
EP-2298764-A1 4-Oxadiazolyl-piperidine compounds and use thereof Purdue Pharma LP (US) 2011-03-23 EP disclosed
EP-2298764-A1 4-Oxadiazolyl-piperidine compounds and use thereof Purdue Pharma LP (US) 2011-03-23 EP disclosed
EP-2298765-A1 4-Oxadiazolyl-piperidine compounds and use thereof Purdue Pharma LP (US) 2011-03-23 EP disclosed
EP-2298765-A1 4-Oxadiazolyl-piperidine compounds and use thereof Purdue Pharma LP (US) 2011-03-23 EP disclosed
EP-2298765-A1 4-Oxadiazolyl-piperidine compounds and use thereof Purdue Pharma LP (US) 2011-03-23 EP disclosed
US-20080319020-A1 4-Oxadiazolyl-Piperidine Compounds and Use Thereof PURDUE PHARMA L.P. 2008-12-25 US disclosed
US-20080319020-A1 4-Oxadiazolyl-Piperidine Compounds and Use Thereof PURDUE PHARMA L.P. 2008-12-25 US disclosed
CN-101312964-A 4-oxadiazolyl piperidine compound and use thereof PURDUE PHARMA LP (US) 2008-11-26 CN disclosed
CN-101312964-A 4-oxadiazolyl piperidine compound and use thereof PURDUE PHARMA LP (US) 2008-11-26 CN disclosed
EP-1951718-A1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF Purdue Pharma LP (US) 2008-08-06 EP disclosed
EP-1951718-A1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF Purdue Pharma LP (US) 2008-08-06 EP disclosed
EP-1896463-A2 NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-12 EP disclosed
WO-2007057229-A1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA L.P. (US) 2007-05-24 WO disclosed
WO-2007057229-A1 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF PURDUE PHARMA L.P. (US) 2007-05-24 WO disclosed
WO-2006123249-A2 NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319020-A1 4-Oxadiazolyl-Piperidine Compounds and Use Thereof VIP, ALPI, OPRD1 HRH4 158/4885USP7 3786/4885SLC18A3 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.